Pierre Foidart/LinkedIn
Mar 21, 2025, 17:36
Pierre Foidart: Patients-related outcomes in OlympiA
Pierre Foidart, Medical oncologist and Head of Clinic at the University Hospital of Liège (CHU de Liège), shared a post on LinkedIn about a paper he co-authored with Guy Jerusalem, published in Gland Surgery:
“Happy to share our editorial comment with Guy Jerusalem on the patients-related outcomes (PRO) in OlympiA.
The PRO study found no evidence of clinically significant increase in fatigue severity after (Neo)Adjuvant chemotherapy in high-risk early breast cancer (EBC) gBRCAm patients treated with 1-year adjuvant Olaparib compared to Placebo.
- It gives reinsurance to physicians on the impact of Olaparib on the quality of life.
- For gBRCAm triple-negative breast cancers: trials investigating the combination of immune checkpoint inhibitors and PARP inhibitors in case of absence of pCR would be of high interest, especially if they consequently aim to discover biomarkers predictive of longer invasive disease-free survival.
- For high-risk gBRCAm hormone receptor+ EBC: expert panel opinion goes in favor of one year of Olaparib followed by 2/3 years of abemaciclib/ribociclib.
- The place of PARPi in neoadjuvant setting remains putative.
- Defining biomarkers of response to PARPi remains very important, both for gBRCAm patients and BRCA wild type patients.”
Authors: Pierre Foidart, Guy Jerusalem.
More posts featuring Pierre Foidart.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 21, 2025, 17:36
Mar 21, 2025, 17:04
Mar 21, 2025, 16:33
Mar 21, 2025, 15:58
Mar 21, 2025, 15:56
Mar 21, 2025, 15:45
Mar 21, 2025, 15:30